AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 8, 2023
The World Health Organization has approved a new vaccine that scientists argue will be a game-changer in the fight against malaria, which kills half a million people in Africa every year.
Bio Pharma Dive
OCTOBER 8, 2023
Mirati shareholders could also receive another $1 billion should an experimental cancer drug the biotech is developing make it to U.S. regulators’ desks.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
BioSpace
OCTOBER 8, 2023
Its reversible nature offers the potential for RNA editing to go beyond rare diseases, eliciting excitement and buy-in from large pharmas like GSK and Eli Lilly.
Fierce Pharma
OCTOBER 8, 2023
After years serving as a rumored target of Big Pharma M&A, Mirati Therapeutics has finally made its sale a reality. | After years serving as a rumored target of Big Pharma M&A, Mirati Therapeutics has finally made its sale a reality. The buyer, Bristol Myers Squibb, will pay up to $5.8 billion for the KRAS drugmaker.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
BioSpace
OCTOBER 8, 2023
Recent FDA approvals of novel drugs based on less-than-stellar clinical evidence point to a trend toward regulatory flexibility—particularly in indications with very high unmet need.
FDA Law Blog
OCTOBER 8, 2023
By Karla L. Palmer — On Friday, October 6, 2023, DEA announced a second extension of telemedicine flexibilities concerning the prescribing of controlled substances, which were originally set to expire after the end of the COVID-19 pandemic emergency. As a reminder, back in February 2023, HPM blogged about DEA’s two proposed rules for prescribing (1) controlled substances generally and (2) for buprenorphine use in opioid treatment.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Drug Patent Watch
OCTOBER 8, 2023
This chart shows the pharmaceutical companies with the most patents in Ecuador. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical companies have the most drug patents in Ecuador? appeared first on DrugPatentWatch - Make Better Decisions.
BioSpace
OCTOBER 8, 2023
Following rumors last week of a potential acquisition by Sanofi, Bristol Myers Squibb on Sunday announced that it paid $4.8 billion to gain access to Mirati Therapeutics’ oncology-focused portfolio.
Drug Patent Watch
OCTOBER 8, 2023
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com The post New tentative approval for Mylan Gmbh drug trastuzumab-dkst appeared first on DrugPatentWatch - Make Better Decisions.
BioSpace
OCTOBER 8, 2023
Despite winning the backing of an FDA advisory committee, the regulator in a Complete Response Letter declined Alnylam’s bid to expand Onpattro’s label to cardiomyopathy in ATTR amyloidosis.
JAMA Internal Medicine
OCTOBER 8, 2023
This cross-sectional study examines whether greater periods of nursing staff turnover are associated with quality of care in US nursing homes.
Expert insights. Personalized for you.
245 
Let's personalize your content